About EyeBio
EyeBio is a company based in London (United Kingdom) founded in 2021 by Anthony Adamis was acquired by Merck Sharp & Dohme in May 2024.. EyeBio has raised $130 million across 2 funding rounds from investors including Merck Sharp & Dohme, Bain Capital Life Sciences and Omega Funds. EyeBio offers products and services including Medicines and Vaccines. EyeBio operates in a competitive market with competitors including EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others.
- Headquarter London, United Kingdom
- Founders Anthony Adamis
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eyebiotech Limited
- Date of Incorporation 09 Jul, 2021
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
$20.88 K (USD)0as on Dec 31, 2022
-
EBITDA
$25.52 K (USD)0as on Dec 31, 2022
-
Total Equity Funding
$130 M (USD)
in 2 rounds
-
Latest Funding Round
$65 M (USD), Series A
Nov 14, 2023
-
Investors
Merck Sharp & Dohme
& 7 more
-
Employee Count
Employee Count
-
Acquired by
Merck Sharp & Dohme
(May 30, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EyeBio
EyeBio offers a comprehensive portfolio of products and services, including Medicines and Vaccines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for diseases like diabetes and oncology
Preventive solutions for infectious diseases
Unlock access to complete
Unlock access to complete
Funding Insights of EyeBio
EyeBio has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $65 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $65.0M
-
First Round
First Round
(22 Feb 2022)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Series A - EyeBio | Valuation | Bain Capital Life Sciences , Omega Funds | |
| Feb, 2022 | Amount | Series A - EyeBio | Valuation | Jeito , SV Health Investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EyeBio
EyeBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck Sharp & Dohme, Bain Capital Life Sciences and Omega Funds. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location | |
|
Venture capital firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EyeBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EyeBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eyebio Comparisons
Competitors of EyeBio
EyeBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Small molecule therapeutics for ophthalmic disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for diseases are developed using DARPin technology.
|
|
| domain | founded_year | HQ Location |
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
|
|
| domain | founded_year | HQ Location |
Gene therapy solutions for retinal diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eyebio
Frequently Asked Questions about EyeBio
When was EyeBio founded?
EyeBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is EyeBio located?
EyeBio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of EyeBio?
David Guyer is the current CEO of EyeBio.
Is EyeBio a funded company?
EyeBio is a funded company, having raised a total of $130M across 2 funding rounds to date. The company's 1st funding round was a Series A of $65M, raised on Feb 22, 2022.
What does EyeBio do?
EyeBio was founded in 2021 and is headquartered in London, United Kingdom. Operations center on the biotechnology sector, where therapies for sight-threatening eye diseases are developed. Focus is placed on next-generation treatments to improve vision, including an anti-vascular endothelial growth factor drug targeted at age-related macular degeneration. Research and development activities are conducted to address unmet needs in ophthalmology.
Who are the top competitors of EyeBio?
EyeBio's top competitors include EyePoint Pharmaceuticals, Rezolute and Molecular Partners.
What products or services does EyeBio offer?
EyeBio offers Medicines and Vaccines.
Who are EyeBio's investors?
EyeBio has 8 investors. Key investors include Merck Sharp & Dohme, Bain Capital Life Sciences, Omega Funds, Vertex Ventures HC, and SV Health Investors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.